Virtu Financial’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Virtu Financial’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$24K	Buy	161,612 +82,103	+103%	+$11.2K	﹤0.01%	1302
2019 Q3	$12K	Buy	79,509 +32,372	+69%	+$5.84K	﹤0.01%	1338
2019 Q2	$8K	Sell	47,137 -231,821	-83%	-$46.9K	﹤0.01%	1394
2019 Q1	$55K	Buy	278,958 +242,994	+676%	+$53.9K	﹤0.01%	1209
2018 Q4	$25K	Buy	35,964 +22,849	+174%	+$25.5K	﹤0.01%	1357
2018 Q3	$16K	Buy	+13,115	New	+$14.7K	﹤0.01%	1426
2017 Q4	–	Sell	-35,862	Closed	-$45K	–	3274
2017 Q3	$45K	Buy	+35,862	New	+$45.8K	﹤0.01%	2243

Other funds holding GNMX

AMCA

Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial's GNMX Position: Q4 2019 in Review

Virtu Financial increased its Aevi Genomic Medicine Inc (GNMX) stake by 103% in Q4 2019, buying an estimated $11.2K and bringing the position to 161,612 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #1302.

Virtu Financial first reported a position in GNMX in Q3 2017 and has held it in 7 quarters since. The position peaked at $55K in Q1 2019. 28 funds tracked by Wall St. Rank hold GNMX as of Q4 2019.

Virtu Financial held 161,612 shares of Aevi Genomic Medicine Inc worth $24K as of Q4 2019.
Virtu Financial bought 82,103 Aevi Genomic Medicine Inc shares in Q4 2019, an estimated $11.2K.
Aevi Genomic Medicine Inc made up ﹤0.01% of Virtu Financial's portfolio in Q4 2019, its #1302 holding.
Virtu Financial first reported a position in Aevi Genomic Medicine Inc in Q3 2017 and has held it in 7 quarters since.
Virtu Financial's Aevi Genomic Medicine Inc position peaked at $55K in Q1 2019.
28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2019.

Based on Virtu Financial's 13F filing for Q4 2019, filed 4 Feb 2020.